Current Methodological Issues in the Economic Assessment of Personalized Medicine
- 31 October 2013
- journal article
- Published by Elsevier BV in Value in Health
- Vol. 16 (6), S20-S26
- https://doi.org/10.1016/j.jval.2013.06.008
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- VALUING THE ECONOMIC BENEFITS OF COMPLEX INTERVENTIONS: WHEN MAXIMISING HEALTH IS NOT SUFFICIENTHealth Economics, 2012
- Methods to elicit experts’ beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulcerationStatistics in Medicine, 2011
- Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic ModelsMedical Decision Making, 2011
- Cost Effectiveness of PharmacogenomicsPharmacoEconomics, 2010
- Valuing the ICECAP capability index for older peopleSocial Science & Medicine, 2008
- Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening ProgrammesPharmacoEconomics, 2008
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004
- New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical InterventionsMedical Decision Making, 2004
- Early Modelling for Assessing Health and Economic Outcomes of Drug TherapyValue in Health, 2000
- The Efficacy of Diagnostic ImagingMedical Decision Making, 1991